AL
ALZN.US Alzamend Neuro Inc
- Market cap
- USD 5.98M
- P/E
- -
- P/B
- 1.09x
- ROE
- -208.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is ALZN.US undervalued?
Graham numberThe Graham number of Alzamend Neuro Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alzamend Neuro Inc fundamental analysis
No fundamental analysis for Alzamend Neuro Inc yet.
Alzamend Neuro Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which …
Full company profileAlzamend Neuro Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Alzamend Neuro Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | - | - | -23.1K | -50.7K | -50.7K | - | -111K |
| Operating Income | -1.55M | -898K | -5.01M | -4.42M | -4.95M | -12.3M | -14.9M | -9.94M | -4.50M | -8.77M | -12.1M |
| EBITDA | 397.00 | 7.43K | -5.01M | -4.42M | -4.95M | -12.3M | -14.8M | -9.89M | -4.45M | -8.66M | -12.0M |
| Net Income | -1.57M | -932K | -4.86M | -4.40M | -5.05M | -12.4M | -14.9M | -9.95M | -4.51M | -8.77M | -12.1M |
| EPS | -74 | -28 | -112 | -83 | -94 | -187 | -206 | -132 | -10 | -2.63 | -2.70 |
| Balance Sheet | |||||||||||
| Total Assets | 132K | 2.42M | 1.50M | 1.81M | 2.91M | 14.5M | 5.92M | 632K | 4.60M | 2.08M | 8.54M |
| Total Liabilities | 717K | 96.7K | 1.18M | 992K | 900K | 1.16M | 2.87M | 3.23M | 635K | 1.35M | 2.74M |
| Shareholders' Equity | -585K | 2.32M | 317K | 822K | 2.01M | 13.4M | 3.05M | -2.59M | 3.97M | 733K | 5.80M |
| Cash & Short-term Investments | 4.98K | 545K | 42.6K | 90.3K | 1.93M | 14.1M | 5.14M | 376K | 3.95M | 711K | 7.59M |
| Total Debt | 591K | - | 79.33 | 62.67 | 335K | - | - | 301K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.42M | -2.05M | -1.05M | -2.35M | -2.71M | -6.61M | -8.92M | -8.27M | -6.57M | -8.07M | -4.55M |
| Capital Expenditure | 0.00 | 0.00 | 106K | 106K | 106K | 106K | 0.00 | 147K | 300K | 0.00 | 0.00 |
| Free Cash Flow | -1.42M | -2.05M | -1.05M | -2.35M | -2.71M | -6.72M | -8.92M | -8.42M | -6.87M | -8.07M | -4.55M |
| Ratios | |||||||||||
| ROE | - | -40.2% | -1,534.3% | -535.0% | -250.7% | -92.6% | -488.5% | - | -113.8% | -1,196.4% | -208.7% |
| ROA | -1,186.8% | -38.6% | -324.0% | -242.4% | -173.3% | -85.2% | -251.5% | -1,575.0% | -98.1% | -421.9% | -141.7% |
| Debt to Equity | - | - | 0.00x | 0.00x | 0.17x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alzamend Neuro Inc dividends
Alzamend Neuro Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:9 on May 12, 2025.
Who owns Alzamend Neuro Inc
- Insiders 2.71%
- Institutions 26.59%
- Public & others 70.71%
- Shares outstanding 4.83M
- Free float 4.81M
Top funds holding ALZN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 19.9K | 0.41% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 4.64K | 0.10% | 0.00% | Sep 2026 |
Top institutions holding ALZN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| KMT WEALTH MANAGEMENT, LLC | 1.33M | 27.54% | 0.00% | Jun 2026 |
| Kingsbury Capital Investment Advisors LLC | 1.12M | 23.21% | -15.74% | Sep 2026 |
| Geode Capital Management, LLC | 26.4K | 0.55% | -42.27% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 21.0K | 0.44% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.56K | 0.16% | +71.73% | Jun 2026 |
| Tower Research Capital LLC | 3.52K | 0.07% | -43.13% | Jun 2026 |
| UBS Group AG | 2.35K | 0.05% | -47.78% | Jun 2026 |
| BlackRock Inc | 437.00 | 0.01% | 0.00% | Jun 2026 |
| IFG Advisory, LLC | 22.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 22.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 3.00 | 0.00% | -25.00% | Jun 2026 |
| HARBOR INVESTMENT ADVISORY, LLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Hartland & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
Alzamend Neuro Inc company profile
- Company name
- Alzamend Neuro Inc
- Ticker
- ALZN.US
- Exchange
- USA Stocks
- Listed since
- Jun 15, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- April
- Address
- 3480 Peachtree Road NE, Atlanta, GA, United States, 30326
- Phone
- 844 722 6333
- Website
- alzamend.com
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro Inc management
5- Mr. Stephan JackmanCEO & Director · born 1976
- Mr. Milton Charles Ault IIIFounder & Vice Chairman · born 1970
- Mr. David J. KatzoffChief Financial Officer · born 1962
- Mr. Henry C. W. Nisser Esq.Executive VP, General Counsel & Director · born 1969
- Mr. Kenneth S. Cragun CPASenior Vice President of Finance · born 1961